Kornimate/medical-research-clean huggingface dataset:
an examination of the use of electrophysiological brain monitoring to direct the treatment of mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: the problem of cognitive decline among the aging population has become a significant health burden, especially in light of the increase in the prevalence of dementia with age for patients with mci (mild cognitive impairment) there are various recommendations to deal with the disorder, including behavioral recommendations for physical exercise. some recommendations could also be found for cognitive practice. however, currently, there is no consensus regarding effective cognitive treatment or practice for mci. among the populations suffering from mci, there is a significant segment of patients with amnestic disorder. for these patients, it seems that cognitive training of memory, including verbal memory, is very important. in recent years, we have developed an effective tool for managing rehabilitation practice by monitoring the patient's engagement with an easy-to-use eeg (electroencephalogram) tool. we have shown in a variety of rehabilitation settings, that when the patient is recruited, the clinical improvement is significantly better. the aim of this study is to evaluate the ability to harness the eeg monitoring of brain engagement to achieve functional improvement in verbal memory training in patients with amnestic mci.


Eligibility criteria:
inclusion criteria: * male or female above the age of 65 years * ability to read, write and understand the hebrew language so to comply with study demands. * diagnosed with amnestic mci. mini mental state examination (mmse), a score of msse ≥27 for college educated subjects and msse ≥ 26 for all others; and (cdr) clinical dementia rating, 0.5 ≥ cdr * diagnosed with memory impairment, visual paired association = vpa (wms-r), for subjects of ages 65-70, 16.5 ≥ wms-r and for subjects of age above 71, 15.5 ≥ wms-r exclusion criteria: * diagnosed with major psychiatric or neurological disorder. * a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence.
placebo controlled metformin and sulfonylurea combination study in patients with type 2 diabetes (0767-025)

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to compare how mk0767 and metformin and sulfonylurea therapy lower blood glucose in patients with inadequate glycemic control this is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (full information is available to trial participants).


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes wtih inadequate glycemic control on maximally effective/tolerated metformin and sulfonylurea therapy * non-pregnant females exclusion criteria: * patients with type 1 diabetes or history of ketoacidosis * patients who have been treated with insulin or other antihyperglycemic agents * patients with viral hepatitis, active liver or gallbladder disease, history of pancreatitis, heart disease, congestive heart failure, inadequately controlled hypertension, hiv positive, history hematologic disorders or neoplastic disease
effect of switching from cigarette smoking to the use of iqos on periodontitis treatment outcome

Conditions: Periodontal Diseases; Chronic Periodontitis; Periodontal Pocket; Tooth Mobility; Gingival Diseases; Smoking, Cigarette

Summary: the purpose of this study was to demonstrate in patients with generalized chronic periodontitis that switching from cigarette smoking to using iqos improves the response to periodontal therapy and the overall oral health status compared to continuing cigarette smoking. note: "iqos" is the tobacco heating system (ths) with marlboro heatsticks, marketed in japan under the brand name iqos

this was a randomized, controlled, open-label, 2-arm, parallel group ambulatory study with the randomization stratified by daily cigarette consumption over the month (30 days) prior to visit 1 (10-19 cigarettes/day vs. \> 19 cigarettes/day) and disease severity recorded at visit 1 (\< 5 mm pocket depth \[pd\] vs. ≥ 5 mm pd) based on the most severely diseased tooth, in smokers with generalized chronic periodontitis who are randomized to either switch from cigarette smoking to iqos use or continuing cigarette smoking.

Eligibility criteria:
main inclusion criteria: 1. patient is aged ≥ 30 years old. 2. patient has smoked on average at least 10 commercially available cigarettes per day for at least 5 years 3. patient has generalized chronic periodontitis (i.e., more than 30% of diseased teeth with a pd ≥ 4 mm). main exclusion criteria: 1. patient has self-reported history of diagnosed systemic diseases (e.g., stroke or acute cardiovascular event within the last 5 years, diabetes, active cancer). 2. patient received root planing therapy within the 6 months prior to visit 1. 3. patient received surgical periodontal therapy within 3 years prior to visit 4. patient was treated within the 3 months prior to visit 1 with systemic antibiotics or was treated with topical antibiotics applied in the mouth. 5. continuous systemic use of steroidal or non-steroidal anti-inflammatory drugs for more than 20 days during the past 30-day period (except for low dose aspirin, i.e., ≤300 mg). 6. female patients who are pregnant, breast-feeding, or planning a pregnancy within the course of the study.

Keywords: oral health smoking cigarette reduced risk product tobacco heating system ths modified risk tobacco product clinical attachment level
nutrition for asthmatics with obesity

Conditions: Asthma; Obesity

Summary: this study will test the effect of diet on asthma in individuals with obesity.

this is a crossover design pilot trial that will recruit 12 adults with obesity and asthma. participants will undergo screening and a lead-in period before being randomized to a series of three, 7-day diets with a 7+ day washout period between each diet. asthma control and lung function will be assessed at the completion of each diet. the goal of this pilot trial is to understand the effect of diet on asthma and conduct an exploratory analysis on factors that may predict the response to diet.

Eligibility criteria:
inclusion criteria: * age: 18-65 years * bmi: 30-45 kg/m2 * asthma diagnosed by medical specialist (confirmed in medical history) * partly controlled or uncontrolled asthma by asthma control test score ≤22 * owns a device compatible with zephyrx platform * stable asthma medication use (no change in the past 2 months). exclusion criteria: * diabetes or using diabetes medications that may lower blood glucose levels * point of care fasting blood glucose ≥126 mg/dl or triglycerides ≥400 mg/dl * current smoking or smoking history of greater than 10 pack-years * other significant respiratory or cardiac disease or the presence of clinically important comorbidities, e.g., copd, renal failure, liver disease; uncontrolled hypertension defined as systolic blood pressure ≥160 mm/hg, or diastolic blood pressure ≥100 mm/hg * pregnant or nursing women * food preferences or allergies inconsistent with study diet capabilities * noncompliance with lead-in period requirements.

Keywords: ketone diet metabolism
psychosocial needs and exploration of online support for patients with mesothelioma

Conditions: Mesothelioma

Summary: the aim of this study is to learn about how mesothelioma affects patients' emotional and physical well-being. also, the investigators would like to learn more about what patients need and how they deal with this illness. this information can help us find ways to lessen physical and emotional strains. part of the study tests an alternate way of giving emotional support through the internet. by providing support online, patients can participate in the comfort of their home.


Eligibility criteria:
inclusion criteria: * diagnosis of pleural mesothelioma and receiving care at mskcc * at least 18 years of age or older * able to read and speak english * patients who choose to participate in the internet-based discussion groups, need a telephone, a computer, internet access, and an e-mail account. exclusion criteria: * significant psychiatric or cognitive disturbance sufficient, in the investigator's judgment, to preclude providing informed consent or participating in a group-format intervention (i.e., acute psychiatric symptoms which require individual treatment).

Keywords: quality of life support group questionnaires internet-based support group 11-066
botulinum toxin type a injection into the gastrocnemius muscle for treatment of nocturnal calf cramps in patients with lumbar spinal stenosis

Conditions: Spinal Stenosis With Nocturnal Calf Cramps

Summary: nocturnal calf cramps is a common complaint in patients with lumbar spinal stenosis. the purpose of this study is to evaluate the effect of botulinum toxin a injection into the gastrocnemius muscle in lumbar spinal stenosis patients receiving conservative therapy. we will compare pain score, insomnia severity, functional ability, patient satisfaction, and neurophysiological variables change using electrical stimulator between control (conservative management for spinal stenosis) and botox group (conservative management for spinal stenosis plus botox injection into the gastrocnemius muscle).


Eligibility criteria:
inclusion criteria: 1. diagnosed lumbar spinal stenosis with mri finding 2. nocturnal calf cramps symptoms at least once per week exclusion criteria: 1. electrolyte disorder 2. congenital muscle disease 3. muscle cramps related medication (statins, diuretics, calcium channel blockers, anticonvulsants etc.) 4. cognitive impairments
single and multiple ascending dose study of amg 171 in subjects with obesity

Conditions: Obesity

Summary: to assess the safety and tolerability of amg 171 as single or multiple doses in subjects with obesity


Eligibility criteria:
inclusion criteria * males and females with ages between 18 and 65 years old, inclusive * except for obesity, otherwise healthy * body mass index (bmi) greater than or equal to 30.0 kg/m2 and less than or equal to 40.0 kg/m2 at screening * other inclusion criteria may apply exclusion criteria: * currently receiving treatment in another investigational device or drug study * women of childbearing potential * history or evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion * other exclusion criteria may apply

Keywords: obesity
treatments and outcomes in patients with primary cutaneous lymphoma

Conditions: Primary Cutaneous Lymphoma

Summary: in order to further improve the diagnosis and treatment level of primary cutaneous lymphoma in china, the national clinical center for skin and immune diseases established a standardized diagnosis and treatment center for primary cutaneous lymphoma to systematically and effectively understand the current treatment status of patients with primary cutaneous lymphoma, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of primary cutaneous lymphoma and help patients with primary cutaneous lymphoma.

primary cutaneous lymphomas (pcls) are defined as non-hodgkin lymphomas presenting in the skin with no evidence of extracutaneous disease at the time of diagnosis. primary cutaneous lymphomas include a heterogeneous group of cutaneous t-cell lymphomas (ctcls) and cutaneous b-cell lymphomas (cbcls). the different types of pcls have highly characteristic clinical and histologic features, often a completely different clinical behavior and prognosis, and require a different type of treatment. various studied in terms of the treatment and outcome of patients with different types of pcls has been conducted in recent years. while the data of chinese patients with pcls are limited. considering the different proportion of pcls and limited treatment modalities in china, a nationwide multi-center prospective study is designed to summarize the current treatment status and outcome of patients.

Eligibility criteria:
inclusion criteria: * patients from the participatin medical centers that has passed the data review of the national clinical center for skin and immune diseases. * patients with a definitive pathological diagnosis of primary cutaneous lymphoma by skin biopsy. exclusion criteria: * patients who fail to provide informed consent form. * patients who cannot complete the questionnaire independently or under the guidance of investigators.

Keywords: primary cutaneous lymphoma treatment survival china non-hodgkin's lymphoma
ideal blood pressure management during endovascular therapy for acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the ideal blood pressure management strategy during endovascular therapy (evt) for acute ischemic stroke has not been defined. the aim of this pilot randomized clinical trial is to determine whether randomization to a standard versus individual blood pressure management strategy during the evt procedure is feasible.

acute ischemic stroke (ais) is a leading cause of death and long-term disability in the western world. catheter-based removal of blood clots (endovascular therapy-evt) is now the standard of care for ais caused by large vessel occlusions in the brain. the level of blood pressure during the procedure appears to influence outcome. however, optimal blood pressure management strategy has not been determined. current blood pressure management strategy during evt typically aims to maintain blood pressure above or within predefined fixed targets and is based on observational data and expert consensus rather than on high-quality randomized evidence. should blood pressure during removal of the occlusion be managed according to the patient's individual blood pressure level or according to predefined fixed blood pressure targets? the primary aim of this pilot trial is to determine whether randomization to a procedure strategy targeting a predefined mean arterial blood pressure (mabp) of 70-90 mmhg versus an individual strategy targeting ± 10 % of a mabp reference value is feasible. secondary aims are to test recruitability and to detect challenges or obstacles that would call for changes in the study design.

Eligibility criteria:
inclusion criteria: * large vessel occlusion in anterior circulation in patients deemed treatable with evt. * living independently (mrs \< 2) before stroke. * evt procedure feasible within 24 hours of symptom onset. exclusion criteria: * contra-indication/allergy to contrast agents, vasopressor agents or anaesthetics. * pregnancy. * medical condition where blood pressure targeting will be problematic (aorta dissection, etc). * participation in another trial.

Keywords: endovascular therapy blood pressure anesthesia
pain in subjects with high capacity cognitive abilities

Conditions: High Cognitive Abilities; Pain; Prevalence

Summary: in many books and website focused in high cognitive abilities talks about pain in these subjects. however, when the investigators look for in sites like pubmed there are no literature about this topic. with this study the investigators will try to know better pain experience in this population and chronic pain prevalence

it's said that people with high cognitive abilities suffered pain. however, there are no scientific literature. with this study the investigators would like to know better pain experience in this population. there are two target groups include inside this population that we consider to study: children population and adults population. the aim of this study is to know the prevalence of chronic pain in this population and to analize the pain experience of this population and the related psychosocial variables that can modify it, like catastrophicing, kinesiophobia, anxiety, quality of life and level of physical activity, the investigators will use a questionnaire that includes different questionnaires like tsk-11sv, pcs, stai, sf-36 and ipaq and many question to evaluate the demographic factor of the sample and the prevalence the investigators will do an statistical analysis to observe the relationship and the predictors factors

Eligibility criteria:
inclusion criteria: * people with a diagnosis of high cognitive abilities exclusion criteria: * people with incapacity to answer the questionnaire * people that's not have a good level of spanish language

Keywords: high cognitive abilities pain prevalence kinesiophobia catastrophising giftedness
prospective electronic polygenic risk study - second phase

Conditions: Coronary Artery Disease; Glaucoma

Summary: this study will investigate the role of polygenic risk scores (prs) in preventive health.

this study will investigate the role of polygenic risk scores (prs) in preventive health. specifically, the purpose of this study is to determine whether knowledge of the degree of coronary artery disease (cad) genetic risk or glaucoma genetic risk, as measured and conveyed by a prs, influences patient and physician decision-making as well as clinical outcomes during short-term (6-month / 2-year) and long-term (3-year / 5-year) follow-up. a cad and glaucoma prs will be calculated for all study participants, with participants randomized to receiving either their cad or glaucoma prs. this study design allows for causal attribution of preventive actions and clinical outcomes to the receipt and degree of genetic risk. the design is informed by a pilot (mygenerank) and phase 1 (peprs first phase) study, with the key extensions being the addition of randomization and increasing the study population size to power causal association with long-term, hard clinical outcomes.

Eligibility criteria:
inclusion criteria: * 45 ≥ age \< 65 * ascvd risk score \> 7.5% as defined by the standard pooled cohort equation * access to and ability to use a smartphone exclusion criteria: * prior diagnosis of coronary disease as defined by prior myocardial infarction (stemi or nstemi), or revascularization (stent or coronary artery bypass grafting) * prior diagnosis or treatment of glaucoma * cerebrovascular disease with history of ischemic stroke, tia, carotid endarterectomy, carotid artery stenting * peripheral arterial disease with history of claudication, revascularization (stents or bypass) * current and active high-intensity statin prescription (rosuvastatin 20 mg, rosuvastatin 40 mg, atorvastatin 40 mg and atorvastatin 80 mg) * anti-pcsk9 therapy * lipid apheresis therapy * currently enrolled in a clinical trial for lipid lowering therapy * known statin intolerance to 2 or more statins in the past
comparison of rf and cryoballoon ablation therapy of af（cryo-af）

Conditions: Atrial Fibrillation

Summary: it's a multi-center, prospective, randomized, controlled clinical trial of cryoballoon versus radiofrequency ablation for paroxysmal atrial fibrillation.

the hypothesis of this study is that pulmonary vein isolation with cryoballoon ablation is not inferior to radiofrequency ablation with 3d mapping with respect to clinical safety and efficacy.

Eligibility criteria:
inclusion criteria: * ecg recording of atrial fibrillation * first time of ablation * refractory to at least one anti-arrhythmia drug * sign informed consent for participation in the study exclusion criteria: * had ablation before * serious heart failure * left atrial diameter\>55mm * myocardial infarction, heart surgery or coronary intervention in 3 months before the ablation * stroke in 6 months before the ablation * endocardial thrombosis

Keywords: atrial fibrillation cryoablation irrigated radiofrequency ablation pulmonary vein isolation
live birth rate between icsi and aoa and icsi alone in patients with severe teratospermia

Conditions: Male Infertility; Teratospermia

Summary: the goal of this clinical trial is to compare the live birth rate between intracytoplasmic sperm injection (icsi) and artificial oocyte activation (aoa) vs intracytoplasmic sperm injection alone in patients with teratospermia. the hypothesis is the live birth rate following icsi and aoa is significantly higher than that by icsi alone in patients with teratospermia. this is a randomized controlled trial. participants will be randomly assigned into one of the two groups: icsi+aoa group: a single sperm will be injected within 4 hours after the follicular aspiration. all injected oocytes will be incubated in the calcium ionophore a23187 activation solution (c9275-1mg, sigma, usa) for 10 min, and cultured in the cleavage medium (cleavage medium , cook, united states) under standard conditions. icsi alone group: a single sperm will be injected within 4 hours after the follicular aspiration.


Eligibility criteria:
inclusion criteria: 1. age of women 20-37 years at the time of ovarian stimulation for icsi 2. at least three matured oocytes severe teratozoospermia: defined as abnormal sperm morphology ranging between 99-100%, including globozoospermia and tapered-head. exclusion criteria: 1. presence of hydrosalpinx which is not surgically treated 2. undergoing preimplantation genetic testing 3. recurrent pregnancy loss (defined as two or more previous spontaneous pregnancy losses) 4. known uterine abnormality (e.g., uterine congenital malformation; untreated uterine septum, adenomyosis, or submucous myoma; endometrial polyps; or intrauterine adhesions) 5. abnormal parental karyotyping, or medical conditions that assisted reproductive technology or pregnancy is contraindicated
erythropoietin in hemolytic uremic syndrome

Conditions: Hemolytic-Uremic Syndrome; Anemia

Summary: this study will evaluate the impact of early administration of erythropoietin in the number of red blood cell transfusions in children with shiga toxin-producing escherichia coli hemolytic uremic syndrome (stec-hus).

introduction: anemia in stec-hus is treated with red blood cell (rbc) transfusions. it can causes hypervolemia, hyperkalemia, exacerbate the thrombotic state of the disease, transmit infectious agents and trigger antigenic sensitization. anemia is mainly due to hemolysis, but deficit of erythropoietin synthesis (epo) may aggravate it. although recombinant human epo is frequently used in children with stec-hus there is no adequate evidence of its benefit. if it is confirmed that epo reduce the number of rbc transfusions, its administration could diminish the aforementioned risks and also reduce costs. objective: to determine if epo administration decreases the number of rbc transfusions and; secondarily, to assess if its levels influence on transfusion requirement. methodology: randomized, open controlled clinical trial. we will include 28 patients (14 per arm) \<18 years with stec-hus admitted to our hospital. they will be grouped after randomization:(1) one to standard of care (rbc transfusions with hemoglobin ≤7 mg / dl and/or hemodynamic instability) and (2) the other to standard of care plus epo (50 u / kg subcutaneous three times weekly) and rbc transfusions with hemoglobin ≤7 mg / dl). serum epo will be measured by elisa and together with the clinical and laboratory variables, association with rbc transfusions number will be sought. written informed consent and assent when appropriate, will be requested prior to enter into the study.

Eligibility criteria:
inclusion criteria: * post diarrheal hus: prodrome of enteritis followed by microangiopathic hemolytic anemia, thrombocytopenia and signs of renal damage (increased plasma creatinine, proteinuria, and / or hematuria). proven stec infection wiil not be required to enter into the study. exclusion criteria: * atypical hus * hus associated with systemic diseases (pneumococcal infection, hiv, systemic lupus erythematosus) or drugs * anemia or known kidney disease * previously transfused or treated with erythropoietin * contraindications to erythropoietin

Keywords: hemolytic-uremic syndrome erythropoietin rbc transfusion